Investors & Media

Recent Event

41st Annual J.P. Morgan Healthcare Conference

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Company Overview

Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The company was founded in 2012, and since 2014 the company’s stock has been publicly traded on Nasdaq under the symbol ATRA.

Atara’s most advanced T-cell immunotherapy in development, tabelecleucel or tab-cel® (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).

Atara is also developing off-the-shelf, allogeneic ATA188 for the potential treatment of multiple sclerosis (MS).

Investor & Media Contacts


Eric Hyllengren
Vice President, Investor Relations & Finance
T: (805) 395-9669


Alex Chapman
Vice President, Corporate Communications & Public Affairs
T: (805) 456-4772

Transfer Agent

Computershare Trust Company, N.A.
P.O. Box 505000
Louisville, KY 40233
T: (781) 575-2879